Loading company…
Pantilogos develops cell and antibody therapies for cancer and autoimmune diseases.
Founded in 2020 in Seoul, Pantilogos is a subsidiary of Eutilex Co., Ltd. Its research focuses on anti-tumor cell and antibody treatments using immunotherapy approaches. In October 2021, the company raised KRW 13 billion in Series A funding from DAYLI Partners and Timeworks Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in